Rapport Therapeutics, Inc. (RAPP) Key Metrics
RAPP valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.32B
- Enterprise value
- $1.22B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 66.1
- Price / book
- 3.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.22
RAPP key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsRAPP valuation Price multiples at each fiscal year-end price.
RAPP returns How much profit the business earns on the capital it uses.
RAPP per-share figures Results divided by the shares outstanding at year-end.
RAPP financial health Debt, liquidity and how easily interest is covered.
RAPP efficiency & capital use Working capital cycle and where the cash goes.
RAPP valuation history
RAPP returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
RAPP debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
RAPP cash returned to shareholders
RAPP price vs earnings per share
RAPP key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $1.43B | $367.9M | — | — |
| Enterprise value | $946.3M | $64.1M | — | — |
| Price / book | 2.9 | 1.2 | — | — |
| Earnings yield | −7.8% | −21.3% | — | — |
| Free cash flow yield | −6.2% | −18.3% | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $30.34 | $17.74 | — | — |
| Per share | ||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$2.37 | −$3.78 | −$1.92 | −$0.53 |
| Operating cash flow per share | −$1.86 | −$3.13 | −$1.50 | −$0.16 |
| Free cash flow per share | −$1.88 | −$3.24 | −$1.59 | −$0.18 |
| Cash per share | $10.44 | $14.72 | $8.16 | $1.55 |
| Book value per share | $10.32 | $14.73 | −$1.42 | $0.97 |
| Tangible book value per share | $10.32 | $14.73 | −$1.42 | $0.97 |
| Capex per share | $0.01 | $0.12 | $0.09 | $0.01 |
| Debt per share | $0.24 | $0.07 | $0.12 | $0.52 |
| Shares outstanding | 47.0M | 20.7M | 18.1M | 20.1M |
| Change in shares outstanding | +126.5% | +14.7% | −10.1% | — |
| Returns & profitability | ||||
| Return on equity (ROE) | −28.2% | −56.0% | — | −54.6% |
| Return on assets (ROA) | −26.9% | −33.3% | −37.2% | −33.7% |
| Return on tangible assets | −21.8% | −24.9% | −22.4% | −33.7% |
| Financial health | ||||
| Total debt | $11.5M | $1.5M | $2.1M | $10.4M |
| Cash & short-term investments | $490.5M | $305.3M | $147.5M | $31.2M |
| Net debt | −$479.1M | −$303.8M | −$145.3M | −$20.7M |
| Debt / equity | 0.02 | 0.00 | — | 0.53 |
| Debt / assets | 0.02 | 0.00 | 0.01 | 0.33 |
| Current ratio | 26.17 | 35.34 | 17.14 | 18.80 |
| Quick ratio | 26.17 | 35.34 | 17.14 | 18.80 |
| Interest coverage | — | — | — | -36.4 |
| Working capital | $479.5M | $301.0M | $142.1M | $29.6M |
| Invested capital | $5.6M | $1.6M | −$171.0M | −$1.2M |
| Tangible asset value | $484.7M | $305.4M | −$25.6M | $19.5M |
| Net current asset value | $470.8M | $300.3M | −$30.2M | $19.2M |
| Graham net-net per share | $9.85 | $14.26 | −$1.86 | $0.95 |
| Capital allocation | ||||
| Share buybacks (net) | $1,000 | $0 | $4,000 | — |
| Capex / depreciation | 0.61 | 2.87 | 14.61 | 18.93 |
| Efficiency | ||||
| Days payables outstanding | 1,102.5 | 969.3 | 6,439.6 | 35,283.3 |
| Payables turnover | 0.33 | 0.38 | 0.06 | 0.01 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $3.1M | $2.2M | $2.0M | $1.4M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from RAPP's annual financial statements (latest annual report filed March 10, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
RAPP valuation and financial ratios
Rapport Therapeutics earned a return on equity of −28.2% in fiscal 2025. It ended the year with $11.5 million of debt and $490.5 million in cash and short-term investments, a net cash position of $479.1 million. It returned $0.0 million to shareholders: $0 in dividends and $0.0 million in share buybacks.
See the RAPP income statement, the RAPP chart for price history, or the RAPP stock overview for the latest quote and news.
RAPP key metrics FAQ
What is Rapport Therapeutics's return on equity?
Rapport Therapeutics's return on equity (ROE) was −28.2% in fiscal 2025: net income of -$111.5 million on average shareholders' equity of $395.0 million.
How much debt does Rapport Therapeutics have?
Rapport Therapeutics had total debt of $11.5 million at the end of fiscal 2025, a debt-to-equity ratio of 0.02 and more cash than debt.
Does Rapport Therapeutics buy back its shares?
Yes. Rapport Therapeutics spent $0.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +126.5% over the year, to 47.0M..
What is Rapport Therapeutics's free cash flow yield?
Rapport Therapeutics generated -$88.1 million of free cash flow in fiscal 2025, a free cash flow yield of −6.2% on its market value at year-end ($1.4 billion).
What is Rapport Therapeutics's current ratio?
Rapport Therapeutics's current ratio was 26.17 at the end of fiscal 2025: current assets were 26.17 times current liabilities.